Nls pharmaceutics announces company update on strategic partnerships

Members of executive leadership team to discuss company update on strategic discussions and timeline of phase 3, nls to webcast its event friday, october 20 at 11:00am et zurich, switzerland / accesswire / october 12, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to issue an important update on discussion the company is having regarding strategic partnerships, including timeline for the company's phase 3 program in narcolepsy the event will be held october 20, 2023, at 11:00 am et and may will include a video stream on the investors section of the company's website.
NLSP Ratings Summary
NLSP Quant Ranking